Hyseq Pharmaceuticals to Present at the BIO CEO & Investor Conference On February 20, 2002
SUNNYVALE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Hyseq Pharmaceuticals, Inc. (Nasdaq: HYSQ - news), today announced that its President and CEO, Ted W. Love, M.D., will present a corporate update at The BIO CEO & Investor Conference 2002 at the Waldorf-Astoria Hotel in New York. The presentation will be held at 3:40 PM E.S.T. on Wednesday, February 20, 2002. For more information, please visit www.bio.org or www.investinbio.com.
A live audio webcast of the presentation will be available online at the BIO CEO & Investor Conference website at www.investinbio.com/ceo2002/index.htm. The presentation is also being webcast by CCBN and can be accessed at Hyseq's website at www.hyseq.com.
The Biotechnology Industry Organization's CEO & Investor Conference is a unique, neutral forum where CEOs from small-, medium- and large-cap companies, as well as private companies planning to go public, can interact with investors and other members of the financial community and the health-care industry. This conference addresses the needs of the entire industry, from the people who run the companies to those who invest in them. The CEO & Investor Conference is structured around 12 investor sessions, six CEO roundtables and a series of individual company presentations.
Hyseq Pharmaceuticals, Inc. is engaged in the research and development of biopharmaceutical products based upon its proprietary database of full-length human gene sequences. Hyseq's screening-by-hybridization platform provided a significant advantage in discovering novel, rarely expressed genes, and assembly of one of the most important proprietary databases of full-length human gene sequences. Hyseq is expanding and accelerating its research activities to further elucidate the role of novel genes in its proprietary database for the development and commercialization of biotherapeutic products. Hyseq's database includes genes which encode a number of therapeutically important classes of molecules including chemokines, growth factors, stem cell factors, interferons, integrins, proteases, hormones, receptors, and other potential protein therapeutics or drug targets. Information about Hyseq is available at www.hyseq.com or by phoning 408-524-8100.
SOURCE: Hyseq Pharmaceuticals, Inc. |
